Why the study?
Does the AngioVac system improve outcomes in patients with right-sided tricuspid valve endocarditis?
Does the AngioVac system improve outcomes in patients with right-sided tricuspid valve endocarditis?
The AngioVac system may be a viable percutaneous option for debulking large vegetations in right-sided infective endocarditis to reduce septic embolization and aid infection clearance.
May support percutaneous debulking in select tricuspid endocarditis; leaves open outcome confirmation in prospective trials.
AngioVac is a vacuum-based device approved in 2014 for percutaneous removal of undesirable materials from the intravascular system. Although numerous reports exist with regard to the use of the AngioVac device in aspiration of iliocaval, pulmonary, upper extremity, and right-sided heart chamber thrombi, very few data are present demonstrating its use in treatment of right-sided endocarditis. In this case report, we describe the novel device used in debulking a large right-sided tricuspid valve vegetation reducing the occurrence of septic embolisation and enhancing the efficacy of antibiotics in clearance of bloodstream infection. Further research is needed in larger RSIE patient populations to confirm the benefits and the potential of improved outcomes associated with the AngioVac device as well as identify its potential complications.
No takes yet. Share an insight, caveat, or question.
Abubakar et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: